BioSpace News Archive

Optimus Healthcare Services, Inc. announced that it received approval notification from the Financial Industry Regulatory Authority for a corporate name change.

SOHM, Inc., generic Pharmaceutical, Nutraceutical, and Cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, announced that the Company has received a semi-annual, bi-monthly order for prescription skincare topical products, estimated to have a top-line revenue value of approximately $500k.

ValnevaSE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced that it has completed recruitment for the pivotal Phase 3 trial of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.

Latest financing will advance the clinical development of its CD8 ImmunoPET agent and build on its market leading position.

Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), and KYE Pharmaceuticals Inc. (“KYE”), today announced a positive decision in their lawsuit in Canadian Federal Court challenging Health Canada’s approval of Medunik’s New Drug Submission (NDS) for Ruzurgi®.

Cantel Medical LLC, formerly known as Cantel Medical Corp., announced that it has delivered a notice to holders of its 3.25% Convertible Senior Notes due 2025, pursuant to the indenture governing the Notes, notifying holders that, as a result of each of the consummation of the series of mergers contemplated by the Agreement and Plan of Merger, dated as of January 12, 2021

VISEN Pharmaceuticals has obtained the investigational new drug (IND) approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the phase III China clinical trial (PaTHway China Trial) of TransCon PTH Solution for Injection

Lab to deliver fast and accurate results for those attending proms and graduation ceremonies3

Hoag’s Pickup Family Neurosciences Institute has started recruiting volunteers for a study testing an investigational treatment that aims to help prevent the earliest stages of memory loss due to Alzheimer’s disease.

The BIOTECanada Board of Directors is pleased to announce the election of Gordon C. McCauley, President and CEO, AdMare BioInnovations, as Chairman of BIOTECanada at ’s Annual General Meeting.